ID   RN213_HUMAN             Reviewed;        5207 AA.
AC   Q63HN8; C9JCP4; D6RI12; F8WKS1; Q658P6; Q69YK7; Q6MZR1; Q8IWF4;
AC   Q8IZX1; Q8IZX2; Q8N406; Q8TEU0; Q9H6C9; Q9H6H9; Q9H6P3; Q9H8A9;
AC   Q9HCF4; Q9HCL8;
DT   20-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   21-MAR-2012, sequence version 3.
DT   04-FEB-2015, entry version 106.
DE   RecName: Full=E3 ubiquitin-protein ligase RNF213;
DE            EC=6.3.2.-;
DE   AltName: Full=ALK lymphoma oligomerization partner on chromosome 17;
DE   AltName: Full=Mysterin;
DE   AltName: Full=RING finger protein 213;
GN   Name=RNF213; Synonyms=ALO17, C17orf27, KIAA1554, KIAA1618, MYSTR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY,
RP   AUTOUBIQUITINATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, VARIANTS
RP   ASP-3962; ASN-4013; GLN-4062; SER-4608; ASN-4863; ASP-4950; VAL-5021;
RP   GLU-5160 AND GLY-5176, AND VARIANT MYMY2 LYS-4810.
RX   PubMed=21799892; DOI=10.1371/journal.pone.0022542;
RA   Liu W., Morito D., Takashima S., Mineharu Y., Kobayashi H., Hitomi T.,
RA   Hashikata H., Matsuura N., Yamazaki S., Toyoda A., Kikuta K.,
RA   Takagi Y., Harada K.H., Fujiyama A., Herzig R., Krischek B., Zou L.,
RA   Kim J.E., Kitakaze M., Miyamoto S., Nagata K., Hashimoto N.,
RA   Koizumi A.;
RT   "Identification of RNF213 as a susceptibility gene for moyamoya
RT   disease and its possible role in vascular development.";
RL   PLoS ONE 6:E22542-E22542(2011).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 3021-5207 (ISOFORMS 1/2).
RC   TISSUE=Endometrium, Lymph node, Melanoma, and Uterus;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Blocker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Kohrer K.,
RA   Ottenwalder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Eye, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M.,
RA   Peck A.M., Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S.,
RA   Feolo M., Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F.,
RA   Schaefer C.F., Buetow K., Bonner T.I., Haussler D., Kent J.,
RA   Kiekhaus M., Furey T., Brent M., Prange C., Schreiber K., Shapiro N.,
RA   Bhat N.K., Hopkins R.F., Hsie F., Driscoll T., Soares M.B.,
RA   Casavant T.L., Scheetz T.E., Brown-stein M.J., Usdin T.B.,
RA   Toshiyuki S., Carninci P., Piao Y., Dudekula D.B., Ko M.S.,
RA   Kawakami K., Suzuki Y., Sugano S., Gruber C.E., Smith M.R.,
RA   Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y., Wei C.L.,
RA   Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W., Fuh E.,
RA   Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D.,
RA   Granite S.J., Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G.,
RA   Blakesly R.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J.,
RA   Schmutz J., Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L.,
RA   Krzywinski M.I., Liao N., Morin R., Morrin R., Palmquist D.,
RA   Petrescu A.S., Skalska U., Smailus D.E., Stott J.M., Schnerch A.,
RA   Schein J.E., Jones S.J., Holt R.A., Baross A., Marra M.A., Clifton S.,
RA   Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-163 (ISOFORMS 1 AND 2/3), AND
RP   CHROMOSOMAL TRANSLOCATION WITH ALK.
RX   PubMed=12112524; DOI=10.1002/gcc.10033;
RA   Cools J., Wlodarska I., Somers R., Mentens N., Pedeutour F., Maes B.,
RA   De Wolf-Peeters C., Pauwels P., Hagemeijer A., Marynen P.;
RT   "Identification of novel fusion partners of ALK, the anaplastic
RT   lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory
RT   myofibroblastic tumor.";
RL   Genes Chromosomes Cancer 34:354-362(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 136-1509 AND 3888-5207
RP   (ISOFORMS 1/2).
RC   TISSUE=Brain;
RX   PubMed=10997877; DOI=10.1093/dnares/7.4.271;
RA   Nagase T., Kikuno R., Nakayama M., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes.
RT   XVIII. The complete sequences of 100 new cDNA clones from brain which
RT   code for large proteins in vitro.";
RL   DNA Res. 7:273-281(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3770-5207 (ISOFORMS 1/2).
RC   TISSUE=Spleen, and Thyroid;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1258, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1258, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1258, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1258, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1258, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-217 AND SER-1258, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1258, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   VARIANTS GLU-2554; VAL-3891; GLY-3915; THR-4399; MET-4567 AND
RP   MET-4765, AND VARIANT MYMY2 LYS-4810.
RX   PubMed=21048783; DOI=10.1038/jhg.2010.132;
RA   Kamada F., Aoki Y., Narisawa A., Abe Y., Komatsuzaki S., Kikuchi A.,
RA   Kanno J., Niihori T., Ono M., Ishii N., Owada Y., Fujimura M.,
RA   Mashimo Y., Suzuki Y., Hata A., Tsuchiya S., Tominaga T.,
RA   Matsubara Y., Kure S.;
RT   "A genome-wide association study identifies RNF213 as the first
RT   Moyamoya disease gene.";
RL   J. Hum. Genet. 56:34-40(2011).
CC   -!- FUNCTION: Probable E3 ubiquitin-protein ligase that may play a
CC       role in angiogenesis. May also have an ATPase activity.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:21799892}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=4;
CC         IsoId=Q63HN8-6; Sequence=VSP_042416, VSP_042420;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q63HN8-5; Sequence=VSP_042419, VSP_042418;
CC       Name=2;
CC         IsoId=Q63HN8-4; Sequence=VSP_042417;
CC         Note=Minor isoform with restricted expression. Gene prediction
CC         based on partial EST data.;
CC       Name=1;
CC         IsoId=Q63HN8-3; Sequence=Displayed;
CC         Note=Major isoform detected in all tissues examined.;
CC   -!- TISSUE SPECIFICITY: Widely expressed (at protein level).
CC       {ECO:0000269|PubMed:21799892}.
CC   -!- DOMAIN: The RING-type zinc finger domain is required for the
CC       ubiquitin-protein ligase activity.
CC   -!- PTM: Autoubiquitinates. {ECO:0000269|PubMed:21799892}.
CC   -!- DISEASE: Moyamoya disease 2 (MYMY2) [MIM:607151]: A progressive
CC       cerebral angiopathy characterized by bilateral intracranial
CC       carotid artery stenosis and telangiectatic vessels in the region
CC       of the basal ganglia. The abnormal vessels resemble a 'puff of
CC       smoke' (moyamoya) on cerebral angiogram. Affected individuals can
CC       develop transient ischemic attacks and/or cerebral infarction, and
CC       rupture of the collateral vessels can cause intracranial
CC       hemorrhage. Hemiplegia of sudden onset and epileptic seizures
CC       constitute the prevailing presentation in childhood, while
CC       subarachnoid bleeding occurs more frequently in adults.
CC       {ECO:0000269|PubMed:21048783, ECO:0000269|PubMed:21799892}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving ALO17 is
CC       associated with anaplastic large-cell lymphoma (ALCL).
CC       Translocation t(2;17)(p23;q25) with ALK.
CC   -!- SIMILARITY: Contains 1 RING-type zinc finger.
CC       {ECO:0000255|PROSITE-ProRule:PRU00175}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH32220.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAB13444.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC       Sequence=BAB14708.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAB15212.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAB15280.1; Type=Erroneous termination; Positions=4257; Note=Translated as Gln.; Evidence={ECO:0000305};
CC       Sequence=BAB15330.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=CAH10615.1; Type=Frameshift; Positions=211, 213, 221, 266; Evidence={ECO:0000305};
CC       Sequence=CAH56189.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ALO17ID480.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB537889; BAK53191.1; -; mRNA.
DR   EMBL; AL832920; CAH10615.1; ALT_FRAME; mRNA.
DR   EMBL; AL833201; CAH56308.1; -; mRNA.
DR   EMBL; BX640932; CAE45967.1; -; mRNA.
DR   EMBL; BX647946; CAH56189.1; ALT_INIT; mRNA.
DR   EMBL; AC123764; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC124319; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC032220; AAH32220.1; ALT_INIT; mRNA.
DR   EMBL; BC036891; AAH36891.1; -; mRNA.
DR   EMBL; BC040341; AAH40341.1; -; mRNA.
DR   EMBL; AF397204; AAN63520.1; -; mRNA.
DR   EMBL; AF397205; AAN63521.1; -; mRNA.
DR   EMBL; AB046774; BAB13380.1; -; mRNA.
DR   EMBL; AB046838; BAB13444.1; ALT_SEQ; mRNA.
DR   EMBL; AK023871; BAB14708.1; ALT_INIT; mRNA.
DR   EMBL; AK025676; BAB15212.1; ALT_INIT; mRNA.
DR   EMBL; AK025914; BAB15280.1; ALT_SEQ; mRNA.
DR   EMBL; AK026038; BAB15330.1; ALT_INIT; mRNA.
DR   EMBL; AK074030; BAB84856.1; -; mRNA.
DR   CCDS; CCDS11772.1; -. [Q63HN8-5]
DR   CCDS; CCDS58606.1; -. [Q63HN8-3]
DR   RefSeq; NP_001243000.2; NM_001256071.2.
DR   RefSeq; NP_066005.2; NM_020954.3. [Q63HN8-5]
DR   UniGene; Hs.195642; -.
DR   UniGene; Hs.740662; -.
DR   UniGene; Hs.745415; -.
DR   ProteinModelPortal; Q63HN8; -.
DR   BioGrid; 121705; 18.
DR   IntAct; Q63HN8; 3.
DR   DMDM; 380865458; -.
DR   MaxQB; Q63HN8; -.
DR   PaxDb; Q63HN8; -.
DR   PRIDE; Q63HN8; -.
DR   DNASU; 57674; -.
DR   Ensembl; ENST00000319921; ENSP00000324392; ENSG00000173821. [Q63HN8-5]
DR   GeneID; 57674; -.
DR   KEGG; hsa:57674; -.
DR   UCSC; uc002jyf.4; human. [Q63HN8-5]
DR   UCSC; uc021uen.2; human. [Q63HN8-3]
DR   CTD; 57674; -.
DR   GeneCards; GC17P078235; -.
DR   H-InvDB; HIX0014240; -.
DR   HGNC; HGNC:14539; RNF213.
DR   HPA; HPA003347; -.
DR   HPA; HPA026790; -.
DR   MIM; 607151; phenotype.
DR   MIM; 613768; gene.
DR   neXtProt; NX_Q63HN8; -.
DR   Orphanet; 2573; Moyamoya disease.
DR   PharmGKB; PA134898812; -.
DR   PharmGKB; PA162401681; -.
DR   eggNOG; NOG86922; -.
DR   GeneTree; ENSGT00630000089884; -.
DR   HOGENOM; HOG000185147; -.
DR   HOVERGEN; HBG073493; -.
DR   InParanoid; Q63HN8; -.
DR   OMA; FLNQIGL; -.
DR   TreeFam; TF343131; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; RNF213; human.
DR   GeneWiki; RNF213; -.
DR   GenomeRNAi; 57674; -.
DR   PMAP-CutDB; Q9HCF4; -.
DR   PRO; PR:Q63HN8; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; Q63HN8; -.
DR   CleanEx; HS_KIAA1618; -.
DR   ExpressionAtlas; Q63HN8; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0016887; F:ATPase activity; IDA:UniProtKB.
DR   GO; GO:0016874; F:ligase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006200; P:ATP catabolic process; IDA:UniProtKB.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   Gene3D; 3.30.40.10; -; 1.
DR   Gene3D; 3.40.50.300; -; 3.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR018957; Znf_C3HC4_RING-type.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   Pfam; PF00097; zf-C3HC4; 1.
DR   SMART; SM00382; AAA; 2.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF52540; SSF52540; 3.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Chromosomal rearrangement; Coiled coil;
KW   Complete proteome; Cytoplasm; Disease mutation; Ligase;
KW   Metal-binding; Phosphoprotein; Proto-oncogene; Reference proteome;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1   5207       E3 ubiquitin-protein ligase RNF213.
FT                                /FTId=PRO_0000415917.
FT   ZN_FING    3997   4036       RING-type. {ECO:0000255|PROSITE-ProRule:
FT                                PRU00175}.
FT   COILED      343    374       {ECO:0000255}.
FT   MOD_RES     217    217       Phosphoserine. {ECO:0000269|PubMed:
FT                                20068231}.
FT   MOD_RES    1258   1258       Phosphoserine. {ECO:0000269|PubMed:
FT                                18318008, ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:18691976}.
FT   VAR_SEQ       1   4650       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_042416.
FT   VAR_SEQ      87     87       E -> EGATSEVLVDAAVDLISDEWEAANAIPSKRRKQDAA
FT                                PLEAASVPSADCEQ (in isoform 2).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_042417.
FT   VAR_SEQ    1009   1063       SQTSILQGFSYSDLRKFGIVLSAVITKSWPRTADNFNDILK
FT                                HLLTLADVKHVFRL -> VNNLSSWETDSGSQLCSAMTQLR
FT                                AMKHPLGLSSSANSEIGKWAPSSLAKGNGAEI (in
FT                                isoform 3). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_042418.
FT   VAR_SEQ    1064   5207       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_042419.
FT   VAR_SEQ    4651   4660       QEQHQLSSRR -> MTRKSAPTSG (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_042420.
FT   VARIANT    2554   2554       D -> E (in dbSNP:rs138516230).
FT                                {ECO:0000269|PubMed:21048783}.
FT                                /FTId=VAR_067020.
FT   VARIANT    3891   3891       M -> V (rare variant detected in a
FT                                sporadic case of Moyamoya disease).
FT                                {ECO:0000269|PubMed:21048783}.
FT                                /FTId=VAR_067021.
FT   VARIANT    3915   3915       E -> G (in dbSNP:rs61740658).
FT                                {ECO:0000269|PubMed:21048783}.
FT                                /FTId=VAR_067022.
FT   VARIANT    3962   3962       N -> D (variant detected in cases of
FT                                Moyamoya disease in Caucasian
FT                                populations). {ECO:0000269|PubMed:
FT                                21799892}.
FT                                /FTId=VAR_067023.
FT   VARIANT    4013   4013       D -> N (variant detected in cases of
FT                                Moyamoya disease in Caucasian
FT                                populations). {ECO:0000269|PubMed:
FT                                21799892}.
FT                                /FTId=VAR_067024.
FT   VARIANT    4062   4062       R -> Q (variant detected in cases of
FT                                Moyamoya disease in Caucasian
FT                                populations). {ECO:0000269|PubMed:
FT                                21799892}.
FT                                /FTId=VAR_067025.
FT   VARIANT    4399   4399       A -> T (in dbSNP:rs148731719).
FT                                {ECO:0000269|PubMed:21048783}.
FT                                /FTId=VAR_067026.
FT   VARIANT    4567   4567       V -> M (rare variant detected in a
FT                                sporadic case of Moyamoya disease; dbSNP:
FT                                rs145282452). {ECO:0000269|PubMed:
FT                                21048783}.
FT                                /FTId=VAR_067027.
FT   VARIANT    4608   4608       P -> S (variant detected in cases of
FT                                Moyamoya disease in Caucasian
FT                                populations). {ECO:0000269|PubMed:
FT                                21799892}.
FT                                /FTId=VAR_067028.
FT   VARIANT    4765   4765       V -> M (rare variant detected in a
FT                                sporadic case of Moyamoya disease).
FT                                {ECO:0000269|PubMed:21048783}.
FT                                /FTId=VAR_067029.
FT   VARIANT    4810   4810       R -> K (in MYMY2; very frequent in
FT                                individuals affected by Moyamoya disease;
FT                                strongly increases the risk of Moyamoya
FT                                disease). {ECO:0000269|PubMed:21048783,
FT                                ECO:0000269|PubMed:21799892}.
FT                                /FTId=VAR_067030.
FT   VARIANT    4863   4863       D -> N (variant detected in cases of
FT                                Moyamoya disease in East Asian
FT                                populations). {ECO:0000269|PubMed:
FT                                21799892}.
FT                                /FTId=VAR_067031.
FT   VARIANT    4950   4950       E -> D (variant detected in cases of
FT                                Moyamoya disease in East Asian
FT                                populations). {ECO:0000269|PubMed:
FT                                21799892}.
FT                                /FTId=VAR_067032.
FT   VARIANT    5021   5021       A -> V (variant detected in cases of
FT                                Moyamoya disease in East Asian
FT                                populations; dbSNP:rs138130613).
FT                                {ECO:0000269|PubMed:21799892}.
FT                                /FTId=VAR_067033.
FT   VARIANT    5160   5160       D -> E (variant detected in cases of
FT                                Moyamoya disease in East Asian
FT                                populations). {ECO:0000269|PubMed:
FT                                21799892}.
FT                                /FTId=VAR_067034.
FT   VARIANT    5176   5176       E -> G (variant detected in cases of
FT                                Moyamoya disease in East Asian
FT                                populations). {ECO:0000269|PubMed:
FT                                21799892}.
FT                                /FTId=VAR_067035.
FT   CONFLICT    270    270       M -> T (in Ref. 4; AAH36891/AAH40341).
FT                                {ECO:0000305}.
FT   CONFLICT    321    321       M -> T (in Ref. 4; AAH36891/AAH40341).
FT                                {ECO:0000305}.
FT   CONFLICT    369    369       K -> N (in Ref. 4; AAH36891).
FT                                {ECO:0000305}.
FT   CONFLICT   1045   1045       N -> D (in Ref. 1; BAK53191 and 6;
FT                                BAB13444). {ECO:0000305}.
FT   CONFLICT   1133   1133       Q -> K (in Ref. 6; BAB13444).
FT                                {ECO:0000305}.
FT   CONFLICT   1195   1195       V -> M (in Ref. 6; BAB13444).
FT                                {ECO:0000305}.
FT   CONFLICT   1272   1272       E -> Q (in Ref. 6; BAB13444).
FT                                {ECO:0000305}.
FT   CONFLICT   1331   1331       D -> G (in Ref. 6; BAB13444).
FT                                {ECO:0000305}.
FT   CONFLICT   3323   3323       R -> G (in Ref. 2; CAH56189).
FT                                {ECO:0000305}.
FT   CONFLICT   4220   4220       E -> G (in Ref. 7; BAB15212).
FT                                {ECO:0000305}.
FT   CONFLICT   4571   4571       D -> G (in Ref. 7; BAB15280).
FT                                {ECO:0000305}.
FT   CONFLICT   4853   4853       K -> R (in Ref. 7; BAB15212).
FT                                {ECO:0000305}.
FT   CONFLICT   4892   4892       N -> S (in Ref. 7; BAB15212).
FT                                {ECO:0000305}.
FT   CONFLICT   5139   5139       L -> S (in Ref. 7; BAB15280).
FT                                {ECO:0000305}.
FT   CONFLICT   5187   5187       L -> P (in Ref. 7; BAB15330).
FT                                {ECO:0000305}.
SQ   SEQUENCE   5207 AA;  591407 MW;  9BA6847099EE6E08 CRC64;
     MECPSCQHVS KEETPKFCSQ CGERLPPAAP IADSENNNST MASASEGEME CGQELKEEGG
     PCLFPGSDSW QENPEEPCSK ASWTVQESKK KKRKKKKKGN KSASSELASL PLSPASPCHL
     TLLSNPWPQD TALPHSQAQQ SGPTGQPSQP PGTATTPLEG DGLSAPTEVG DSPLQAQALG
     EAGVATGSEA QSSPQFQDHT EGEDQDASIP SGGRGLSQEG TGPPTSAGEG HSRTEDAAQE
     LLLPESKGGS SEPGTELQTT EQQAGASASM AVDAVAEPAN AVKGAGKEMK EKTQRMKQPP
     ATTPPFKTHC QEAETKTKDE MAAAEEKVGK NEQGEPEDLK KPEGKNRSAA AVKNEKEQKN
     QEADVQEVKA STLSPGGGVT VFFHAIISLH FPFNPDLHKV FIRGGEEFGE SKWDSNICEL
     HYTRDLGHDR VLVEGIVCIS KKHLDKYIPY KYVIYNGESF EYEFIYKHQQ KKGEYVNRCL
     FIKSSLLGSG DWHQYYDIVY MKPHGRLQKV MNHITDGPRK DLVKGKQIAA ALMLDSTFSI
     LQTWDTINLN SFFTQFEQFC FVLQQPMIYE GQAQLWTDLQ YREKEVKRYL WQHLKKHVVP
     LPDGKSTDFL PVDCPVRSKL KTGLIVLFVV EKIELLLEGS LDWLCHLLTS DASSPDEFHR
     DLSHILGIPQ SWRLYLVNLC QRCMDTRTYT WLGALPVLHC CMELAPRHKD AWRQPEDTWA
     ALEGLSFSPF REQMLDTSSL LQFMREKQHL LSIDEPLFRS WFSLLPLSHL VMYMENFIEH
     LGRFPAHILD CLSGIYYRLP GLEQVLNTQD VQDVQNVQNI LEMLLRLLDT YRDKIPEEAL
     SPSYLTVCLK LHEAICSSTK LLKFYELPAL SAEIVCRMIR LLSLVDSAGQ RDETGNNSVQ
     TVFQGTLAAT KRWLREVFTK NMLTSSGASF TYVKEIEVWR RLVEIQFPAE HGWKESLLGD
     MEWRLTKEEP LSQITAYCNS CWDTKGLEDS VAKTFEKCII EAVSSACQSQ TSILQGFSYS
     DLRKFGIVLS AVITKSWPRT ADNFNDILKH LLTLADVKHV FRLCGTDEKI LANVTEDAKR
     LIAVADSVLT KVVGDLLSGT ILVGQLELII KHKNQFLDIW QLREKSLSPQ DEQCAVEEAL
     DWRREELLLL KKEKRCVDSL LKMCGNVKHL IQVDFGVLAV RHSQDLSSKR LNDTVTVRLS
     TSSNSQRATH YHLSSQVQEM AGKIDLLRDS HIFQLFWREA AEPLSEPKED QEAAELLSEP
     EEESERHILE LEEVYDYLYQ PSYRKFIKLH QDLKSGEVTL AEIDVIFKDF VNKYTDLDSE
     LKIMCTVDHQ DQRDWIKDRV EQIKEYHHLH QAVHAAKVIL QVKESLGLNG DFSVLNTLLN
     FTDNFDDFRR ETLDQINQEL IQAKKLLQDI SEARCKGLQA LSLRKEFICW VREALGGINE
     LKVFVDLASI SAGENDIDVD RVACFHDAVQ GYASLLFKLD PSVDFSAFMK HLKKLWKALD
     KDQYLPRKLC DSARNLEWLK TVNESHGSVE RSSLTLATAI NQRGIYVIQA PKGGQKISPD
     TVLHLILPES PGSHEESREY SLEEVKELLN KLMLMSGKKD RNNTEVERFS EVFCSVQRLS
     QAFIDLHSAG NMLFRTWIAM AYCSPKQGVS LQMDFGLDLV TELKEGGDVT ELLAALCRQM
     EHFLDSWKRF VTQKRMEHFY LNFYTAEQLV YLSTELRKQP PSDAALTMLS FIKSNCTLRD
     VLRASVGCGS EAARYRMRRV MEELPLMLLS EFSLVDKLRI IMEQSMRCLP AFLPDCLDLE
     TLGHCLAHLA GMGGSPVERC LPRGLQVGQP NLVVCGHSEV LPAALAVYMQ TPSQPLPTYD
     EVLLCTPATT FEEVALLLRR CLTLGSLGHK VYSLLFADQL SYEVARQAEE LFHNLCTQQH
     REDYQLVMVC DGDWEHCYLP SAFSQHKVFV TPQAPLEAIQ AYLAGHYRVP KQTLSAAAVF
     NDRLCVGIVA SERAGVGKSL YVKRLHDKMK MQLNVKNVPL KTIRLIDPQV DESRVLGALL
     PFLDAQYQKV PVLFHLDVTS SVQTGIWVFL FKLLILQYLM DINGKMWLRN PCHLYIVEIL
     ERRTSVPSRS SSALRTRVPQ FSFLDIFPKV TCRPPKEVID MELSALRSDT EPGMDLWEFC
     SETFQRPYQY LRRFNQNQDL DTFQYQEGSV EGTPEECLQH FLFHCGVINP SWSELRNFAR
     FLNYQLRDCE ASLFCNPSFI GDTLRGFKKF VVTFMIFMAR DFATPSLHTS DQSPGKHMVT
     MDGVREEDLA PFSLRKRWES EPHPYVFFND DHTTMTFIGF HLQPNINGSV DAISHLTGKV
     IKRDVMTRDL YQGLLLQRVP FNVDFDKLPR HKKLERLCLT LGIPQATDPD KTYELTTDNM
     LKILAIEMRF RCGIPVIIMG ETGCGKTRLI KFLSDLRRGG TNADTIKLVK VHGGTTADMI
     YSRVREAENV AFANKDQHQL DTILFFDEAN TTEAISCIKE VLCDHMVDGQ PLAEDSGLHI
     IAACNPYRKH SEEMICRLES AGLGYRVSME ETADRLGSIP LRQLVYRVHA LPPSLIPLVW
     DFGQLSDVAE KLYIQQIVQR LVESISLDEN GTRVITEVLC ASQGFMRKTE DECSFVSLRD
     VERCVKVFRW FHEHSAMLLA QLNAFLSKSS VSKNHTERDP VLWSLMLAIG VCYHASLEKK
     DSYRKAIARF FPKPYDDSRL LLDEITRAQD LFLDGVPLRK TIAKNLALKE NVFMMVVCIE
     LKIPLFLVGK PGSSKSLAKT IVADAMQGPA AYSDLFRSLK QVHLVSFQCS PHSTPQGIIS
     TFRQCARFQQ GKDLQQYVSV VVLDEVGLAE DSPKMPLKTL HPLLEDGCIE DDPAPHKKVG
     FVGISNWALD PAKMNRGIFV SRGSPNETEL IESAKGICSS DILVQDRVQG YFASFAKAYE
     TVCKRQDKEF FGLRDYYSLI KMVFAAAKAS NRKPSPQDIA QAVLRNFSGK DDIQALDIFL
     ANLPEAKCSE EVSPMQLIKQ NIFGPSQKVP GGEQEDAESR YLLVLTKNYV ALQILQQTFF
     EGDQQPEIIF GSGFPKDQEY TQLCRNINRV KICMETGKMV LLLNLQNLYE SLYDALNQYY
     VHLGGQKYVD LGLGTHRVKC RVHPNFRLIV IEEKDVVYKH FPIPLINRLE KHYLDINTVL
     EKWQKSIVEE LCAWVEKFIN VKAHHFQKRH KYSPSDVFIG YHSDACASVV LQVIERQGPR
     ALTEELHQKV SEEAKSILLN CATPDAVVRL SAYSLGGFAA EWLSQEYFHR QRHNSFADFL
     QAHLHTADLE RHAIFTEITT FSRLLTSHDC EILESEVTGR APKPTLLWLQ QFDTEYSFLK
     EVRNCLTNTA KCKILIFQTD FEDGIRSAQL IASAKYSVIN EINKIRENED RIFVYFITKL
     SRVGRGTAYV GFHGGLWQSV HIDDLRRSTL MVSDVTRLQH VTISQLFAPG DLPELGLEHR
     AEDGHEEAME TEASTSGEVA EVAEEAMETE SSEKVGKETS ELGGSDVSIL DTTRLLRSCV
     QSAVGMLRDQ NESCTRNMRR VVLLLGLLNE DDACHASFLR VSKMRLSVFL KKQEESQFHP
     LEWLAREACN QDALQEAGTF RHTLWKRVQG AVTPLLASMI SFIDRDGNLE LLTRPDTPPW
     ARDLWMFIFS DTMLLNIPLV MNNERHKGEM AYIVVQNHMN LSENASNNVP FSWKIKDYLE
     ELWVQAQYIT DAEGLPKKFV DIFQQTPLGR FLAQLHGEPQ QELLQCYLKD FILLTMRVST
     EEELKFLQMA LWSCTRKLKA ASEAPEEEVS LPWVHLAYQR FRSRLQNFSR ILTIYPQVLH
     SLMEARWNHE LAGCEMTLDA FAAMACTEML TRNTLKPSPQ AWLQLVKNLS MPLELICSDE
     HMQGSGSLAQ AVIREVRAQW SRIFSTALFV EHVLLGTESR VPELQGLVTE HVFLLDKCLR
     ENSDVKTHGP FEAVMRTLCE CKETASKTLS RFGIQPCSIC LGDAKDPVCL PCDHVHCLRC
     LRAWFASEQM ICPYCLTALP DEFSPAVSQA HREAIEKHAR FRQMCNSFFV DLVSTICFKD
     NAPPEKEVIE SLLSLLFVQK GRLRDAAQRH CEHTKSLSPF NDVVDKTPVI RSVILKLLLK
     YSFHDVKDYI QEYLTLLKKK AFITEDKTEL YMLFINCLED SILEKTSAYS RNDELNHLEE
     EGRFLKAYSP ASRGREPANE ASVEYLQEVA RIRLCLDRAA DFLSEPEGGP EMAKEKQCYL
     QQVKQFCIRV ENDWHRVYLV RKLSSQRGME FVQGLSKPGR PHQWVFPKDV VKQQGLRQDH
     PGQMDRYLVY GDEYKALRDA VAKAVLECKP LGIKTALKAC KTPQSQQSAY FLLTLFREVA
     ILYRSHNASL HPTPEQCEAV SKFIGECKIL SPPDISRFAT SLVDNSVPLL RAGPSDSNLD
     GTVTEMAIHA AAVLLCGQNE LLEPLKNLAF SPATMAHAFL PTMPEDLLAQ ARRWKGLERV
     HWYTCPNGHP CSVGECGRPM EQSICIDCHA PIGGIDHKPR DGFHLVKDKA DRTQTGHVLG
     NPQRRDVVTC DRGLPPVVFL LIRLLTHLAL LLGASQSSQA LINIIKPPVR DPKGFLQQHI
     LKDLEQLAKM LGHSADETIG VVHLVLRRLL QEQHQLSSRR LLNFDTELST KEMRNNWEKE
     IAAVISPELE HLDKTLPTMN NLISQDKRIS SNPVAKIIYG DPVTFLPHLP RKSVVHCSKI
     WSCRKRITVE YLQHIVEQKN GKERVPILWH FLQKEAELRL VKFLPEILAL QRDLVKQFQN
     VQQVEYSSIR GFLSKHSSDG LRQLLHNRIT VFLSTWNKLR RSLETNGEIN LPKDYCSTDL
     DLDTEFEILL PRRRGLGLCA TALVSYLIRL HNEIVYAVEK LSKENNSYSV DAAEVTELHV
     ISYEVERDLT PLILSNCQYQ VEEGRETVQE FDLEKIQRQI VSRFLQGKPR LSLKGIPTLV
     YRHDWNYEHL FMDIKNKMAQ DSLPSSVISA ISGQLQSYSD ACEVLSVVEV TLGFLSTAGG
     DPNMQLNVYT QDILQMGDQT IHVLKALNRC QLKHTIALWQ FLSAHKSEQL LRLHKEPFGE
     ISSRYKADLS PENAKLLSTF LNQTGLDAFL LELHEMIILK LKNPQTQTEE RFRPQWSLRD
     TLVSYMQTKE SEILPEMASQ FPEEILLASC VSVWKTAAVL KWNREMR
//
